Proteomic analysis of HBV-associated HCC: Insights on mechanisms of disease onset and biomarker discovery

The development of hepatocellular carcinoma (HCC) can be considered as an end-stage outcome of chronic hepatitis B virus (HBV) infection. Early prognostic markers are needed to allow effective treatments and prevent HCC from developing. Proteomics analysis has been used to identify markers from clin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteomics 2010-05, Vol.73 (7), p.1283-1290
Main Authors: Niu, Dandan, Feng, Huixing, Chen, Wei Ning
Format: Article
Language:English
Subjects:
Biological and medical sciences
Diverse techniques
Fundamental and applied biological sciences. Psychology
Gastroenterology. Liver. Pancreas. Abdomen
HBX
Hepatitis B virus (HBV)
Hepatocellular carcinoma (HCC)
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Molecular and cellular biology
Prognostic biomarkers
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of hepatocellular carcinoma (HCC) can be considered as an end-stage outcome of chronic hepatitis B virus (HBV) infection. Early prognostic markers are needed to allow effective treatments and prevent HCC from developing. Proteomics analysis has been used to identify markers from clinical samples from HCC patients. This approach can be further improved by identifying early biomarkers before the onset of HCC. One way would be to use the cell-based HBV replication system, which is reflective of the early stage of virus infection and thus secreted proteins identified at this stage may have relevance in HCC prognosis. In this review, we focus the discussion on the current status of proteomics analysis of cellular proteins and HCC biomarker identification, with a special highlight on the potential of the cell-based HBV replication system for the identification of prognostic HCC biomarkers. Cell-based proteomics platform for analysis of mechanisms of liver diseases and identification of prognostic biomarkers. For example, new approach in identifying targets involved in HBV-mediated epigenetic gene regulation. [Display omitted] n1number of proteins down-regulated in HBV-producing HepG2.2.15 as compared with HepG2n2number of proteins reactivated in HepG2.2.15 after the 5-Aza-dC treatment.Nnumber of proteins involved in HBV-mediated epigenetic gene regulation
ISSN:1874-3919
DOI:10.1016/j.jprot.2010.02.016